Find safer, cleaner and greener products at: rjmnanotech.com

MY-SHIELD®

TOPICAL ANTISEPTIC GEL

THE WOUND CARE MIRACLE

Introducing My-shield® Topical Antiseptic Gel, a USA, GLP (Good Laboratory Practice) manufactured nano silicone/based FDA approved, over-the-counter, 0.13% Benzalkonium chloride pre-priority formulation.

Designed specifically to promote rapid infection free healing of minor cuts, deep wounds, abrasions and burns. Superior to all current prescription and OTC (over-the-counter) products available in the USA today.

My-shield® Topical Antiseptic Gel was developed to provide long-lasting, alcohol-free protection from germs when applied to minor cuts, deep wounds, abrasions and burns. With the addition of our proprietary formula Zertrisil®, it not only controls wound bacterial contamination, it promotes rapid wound healing & prevents future bacterial wound re-infections.

Formulated with

Zetrisil™

A PROPRIETARY SILICONE QUATERNARY SOLUTION

WHAT IS ZETRISIL® AND HOW DOES IT HELP WITH WOUND HEALING?

Zetrisil® is a proprietary nano-based silicone compound combined with conventional quaternary ammonium compounds, that effectively protects and/or "shields" the effected area from bacterial contamination, by way of a long-lasting, cationic charged, anti microbial nano silicone coating.

CLINICAL PRODUCT TRIAL RESULTS

SUBJECT #1:

92 year old female still living in her own home under the care of her son within her home and her daughter across the street. Patient is known to be protein malnourished with Stage III Chronic Renal Failure.

DATE OF TRIAL:

Commenced on the 26th of April, 2019

TRIAL CONDUCTED BY:

Choisser Medical Group, Orange Park, Florida, USA

PHYSICIAN OVERSEEING TRIAL:

William V. Choisser, M.D.
Shane McClanahan, PA-C via housecall services

RELEVANT PRESCRIPTION MEDICATION:

- Eliquis® (blood thinner) due to recent DVT and pulmonary embolism
- Spironolactone & Lasix diuretics for CHF
- Levothyroxine to treat Hypothyroidism

RELEVANT PATIENT PHYSICAL CONDITION:

Advanced age structural and functional skin degeneration, large 15 com x 4 cm laceration to the right shin with partial depth skin & tissue loss occurred on 4-21-19 and treated by family members with Triple Antibiotic Ointment for 4 days. Physician Assistant Shane McClanahan was contacted on day 5 and My-shield® Topical Antiseptic Gel was applied liberally with Keflex antibiotic administered due to early cellulitis.

TREATMENT DETAILS:

My-shield® Topical Antiseptic Gel was applied liberally over the entire wound, covered with sterile petrolatum mesh (note crosshatched pattern on new tissue) and covered with Teflon non-adherent dressing and padded with dry gauze and wrapped with roller gauze to avoid tape contacting the skin. The treatment process was repeated once daily from the 26th of April, 2019 to the 3rd of May, 2019 when the Teflon dressing was discontinued due to minimal wound exudate. My-shield® Topical Antiseptic Gel was continued through May 20th, 2019 (complete wound closure) with recommended follow up application of My-shield® Topical Antiseptic Gel once daily for 7 more days. Wound debridement was never attempted due to patient's emotional state and was found to be completely unnecessary due to the speed of wound remodeling, closure and healing.

OBSERVATIONS TO THE RAPID IMPROVEMENT IN THE PATIENT'S WOUND CAN BE ATTRIBUTED TO THE FOLLOWING MECHANISMS:

- Improved functional parallel formation of collagen Type I production.
- Reduction in bacterial and or bacterial biofilm contamination, thus reducing bacterial produced endotoxins that may slow would healing & tissue regeneration
- Upregulation of TGF beta and fibrillin, closed the wound openings quickly.
- Stimulated protein production and growth factors, no hypertrophic scarring or keloid formation on the healing tissue.

PHOTOS DOCUMENTING TREATMENT:

The treatment process was repeated once daily from April 26th, 2019 to May 3rd, 2019 when the Teflon dressing was discontinued due to minimal wound exudate. My-shield® Topical Antiseptic Gel was continued through June 4th, 2019



4/26/19



5/03/19 (7 Days)



5/22/19 (25 Days)



6/04/19 (38 Days)

RJM NanoTech, LLC | 1002 Gemini - Suite 224 | Houston, TX 77062 | info@rjmnanotech.com | (713) 724 - 1631

SUBJECT #2:
77 year old male quadriplegic

DATE OF TRIAL:
Commenced on the 20th of May, 2019

TRIAL CONDUCTED BY:
Choisser Medical Group, Orange Park, Florida, USA

RELEVANT PRESCRIPTION MEDICATION:
None

PHYSICIAN OVERSEEING TRIAL:
William V. Choisser, M.D.
Shane McClanahan, PA-C via housecall services

RELEVANT PATIENT PHYSICAL CONDITION:
Well-nourished and otherwise healthy, this patient had a large crusty lesion involving his right temple. For over 15 years he had been able to scrub it aggressively in the shower and kept it from thickening. Following a sudden vertebral abscess, he became a quadriplegic and the lesion has been enlarging and thickening.

He was seen by a dermatologist who aggressively, sharply excised the lesion, leaving a full thickness wound cavity with some fat visible at the deepest portion. Unfortunately, there is no identification of pathology available on this lesion. Patient's wife left the post-operative dressing in place for the recommended 48 hrs. When the wife removed the dressing, she found a thick, greenish biofilm filling the void. Topical Gel was already in the home being used to treat a superficially infected abdominal wound around a leaky suprapubic stoma.

TREATMENT DETAILS:
Image #1 below shows the wound when the first dressing was removed and wife and Home Care RN were told to apply My-shield® Topical Antiseptic Gel once daily, then cover with Telfa and then Vasoline gauze to prevent sticking to the wound. There was no debridement done at any time with this wound and all biofilm removal was accomplished with My-shield® Topical Antiseptic Gel breaking it down daily. Dressing was changed once daily through the series of pictures with Vasoline gauze discontinued when wound discharge resolved. Telfa and gel continued through complete healing.

OBSERVATIONS TO THE RAPID IMPROVEMENT IN THE PATIENT'S WOUND CAN BE ATTRIBUTED TO THE FOLLOWING MECHANISMS:
During the first week of treatment, Biofilm dissolving, active granulation and rapid healing was in progress. Minimal exudate and no surrounding superficial infection or inflammation were present. After the first week of treatment, the deepest area of the lesion wound was not yet filled in to the level of preoperative tissue of the temple. During the last 2 weeks of treatment, My-shield® Topical Antiseptic Gel was only used in the remaining open areas of the wound.

PHOTOS DOCUMENTING TREATMENT:
The treatment process was repeated once daily from May 20th, 2019 to June 1st , 2019


5/20/19


5/23/19 (3 Days)


5/27/19 (7 Days)


6/01/19 (12 Days)